iPRIME members Dr. Loren Erickson and Dr. John Lukens received an NOA supplement for their project “IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosis”.  Congratulations to their team for their excellent work investigating the link between alpha-gal and CVD.  We are excited to see and promote the results of this important study!